- In January 2025, Arvinas Inc. reported encouraging Phase 2 clinical trial results for its PROTAC protein degraders, ARV-471 and ARV-766, in treating metastatic castration-resistant prostate cancer (mCRPC). The trials demonstrated a clinical benefit rate of 38% in evaluable patients, with both drugs exhibiting a favorable tolerability profile
- In April 2024, Arvinas, Inc. entered into a strategic license agreement with Novartis for the global development and commercialization of ARV-766, a second-generation PROTAC androgen receptor degrader aimed at treating prostate cancer
- In December 2023, The Austrian Science Fund approved a four-year extension for the Special Research Program (SFB) in Targeted Protein Degradation, focusing on advancing methods to target specific proteins for degradation, with potential applications in drug discovery and therapeutic interventions
- In November 2024, C4 Therapeutics announced a strategic discovery research collaboration with Merck KGaA to target critical oncogenic proteins using C4T’s proprietary Degronimid platform technology, aiming to advance the development of next-generation oncology therapies
